Salinomycin, a polyether ionophore antibiotic isolated from Streptomyces albus, both targets on human cancer stem cells and works as an an antibacterial and coccidiostat compound[1][2]. Salinomycin exhibited selective toxicity for mesenchymally transdifferentiated epithelial cells. Salinomycin reduced the proportion of CSCs by >100-fold relative to paclitaxel. Pretreatment with salinomycin resulted in a >100-fold decrease in tumor-seeding ability relative to paclitaxel pre-treatment for both the HMLER and 4T1 cancer lines. Daily intraperitoneal administration of 5mg/kg salinomycin delayed palpable tumor formation by 2 weeks in mice xenograft SUM159 cells, with increased necrosis and apoptosis, and focally expressed E-cadherin protein observed[1]. The killing CSCs activity of salinomycin is most likely by interfering with ABC drug transporters, the Wnt/β-catenin signaling pathway, and other CSC pathways[2]. The role of salinomycin involving in autophagy may also account for its anticancer effects[3].
作用机制
The effect of salinomycin on ABC drug transporters, the Wnt/β-catenin signaling pathway, and other CSC pathways, as well as autophagy, may contribute to the anticancer effects of salinomycin.[1][2][3]
Salinomycin 细胞研究
细胞系
浓度
检测类型
检测时间
活动说明
数据源
BALB/3T3 cells
Cytotoxicity assay
72 h
Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay, IC50=28.08 μM
23079523
HL60 cells
Proliferation assay
72 h
Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.29 μM
25644674
HL60/Vinc cells
Cytotoxicity assay
72 h
Cytotoxicity against vincristine-resistant human HL60/Vinc cells incubated for 72 hrs by MTT assay, IC50=3.44 μM
23079523
HT-29 cells
Proliferation assay
72 h
Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method, IC50=1.03 μM
搜索
